NC
ALNY icon

nVerses Capital’s Alnylam Pharmaceuticals ALNY Stock Holding History

nVerses Capital’s Portfolio ALNY Stock Details ALNY Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q3 		– Sell
-100
Closed -$24.3K – 979
2024
Q2 		$24.3K Buy
+100
New +$15.8K 0.01% 755

Other funds holding ALNY

Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return
Dodge & Cox
Dodge & Cox San Francisco, California $182B AUM 14.68% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

nVerses Capital's ALNY Position: Q3 2024 in Review

nVerses Capital sold out of Alnylam Pharmaceuticals (ALNY) in Q3 2024, closing a stake of 100 shares — an estimated $24.3K sold.

nVerses Capital first reported a position in ALNY in Q2 2024 and held it in 1 quarter. The position peaked at $24.3K in Q2 2024. 566 funds tracked by Wall St. Rank hold ALNY as of Q3 2024.

  • nVerses Capital reported no remaining Alnylam Pharmaceuticals position as of Q3 2024 after selling out during the quarter.
  • nVerses Capital sold 100 Alnylam Pharmaceuticals shares in Q3 2024, an estimated $24.3K.
  • nVerses Capital first reported a position in Alnylam Pharmaceuticals in Q2 2024 and held it in 1 quarter.
  • nVerses Capital's Alnylam Pharmaceuticals position peaked at $24.3K in Q2 2024.
  • 566 funds tracked by Wall St. Rank held Alnylam Pharmaceuticals as of Q3 2024.

Based on nVerses Capital's 13F filing for Q3 2024, filed 16 Oct 2024.